✦ LIBER ✦

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines

✍ Scribed by Cosette M. Wheeler; Oliver M. Bautista; Joanne E. Tomassini; Margaret Nelson; Carlos A. Sattler; Eliav Barr

Book ID: 116960221
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 344 KB
Volume: 26
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2007.11.043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, immunogenicity, and efficacy of

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

✍ Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. Garc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naï

Induction of immune memory following adm

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

✍ Sven-Eric Olsson; Luisa L. Villa; Ronaldo L.R. Costa; Carlos A. Petta; Rosires P 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 442 KB

PS10 Late breaking Prophylactic use of q

PS10 Late breaking Prophylactic use of quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine reduces cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma in situ (AIS) risk

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Prophylactic quadrivalent human papillom

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

✍ Luisa L Villa; Ronaldo LR Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 109 KB

Dose-ranging studies of the safety and i

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

✍ Kenneth H Fife; Cosette M Wheeler; Laura A Koutsky; Eliav Barr; Darron R Brown; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Efficacy of a quadrivalent prophylactic

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

✍ Elmar A Joura; Sepp Leodolter; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonz 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 165 KB